Genomic profiling of breast cancer

Journal of Surgical Oncology

Volumn 99, Issue 6, 2009, Pages 386-392

  Pandey, Anjita ^a   Singh, Alok Kumar ^b   Maurya, Sanjeev Kumar ^a   Rai, Rajani ^a   Tewari, Mallika ^a   Kumar, Mohan ^a   Shukla, Hari S ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

Breast cancer; Carcinogen metabolism genes; DNA repair genes; Proto oncogenes; Tumor suppressor genes

Indexed keywords

BREAST CANCER; CANCER GROWTH; CARCINOGEN METABOLISM GENE; CARCINOGENESIS; CHROMOSOMAL LOCALIZATION; DNA REPAIR GENE; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENETIC SUSCEPTIBILITY; HUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE; ARTICLE; BREAST TUMOR; DNA METHYLATION; DNA REPAIR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOSITY LOSS; HUMAN CHROMOSOME; HUMAN GENOME; METABOLISM;

CARCINOGEN;

BREAST NEOPLASMS; CARCINOGENS; CHROMOSOMES, HUMAN; DNA METHYLATION; DNA REPAIR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENOME, HUMAN; HUMANS; LOSS OF HETEROZYGOSITY; PROTO-ONCOGENES;

EID: 65449125449     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21249     Document Type: Review

References (85)

1. Metz CW: The American society of naturalists - Duplication of chromosome parts as a factor in evolution. Am Nat 1947;81:81-103.
2. American Cancer Society. Cancer facts and figures 2005. Atlanta, GA:American Cancer Society. 2005.
3. Stewart SL, King JB, Thompson TD, et al.: Cancer mortality surveillance-United States, 1990-2000. Morbidity & Mortality Weekly Report. 2004;53:1-108.
4. Rao DN, Ganesh B: Estimate of cancer incidence in India in 1991. Indian J Cancer 1998;35:10-18.
5. Kuraparthy S, Reddy KM, Yadagiri LA, et al.: Epidemiology and patterns of care for invasive breast carcinoma at a community hospital in Southern India. World J Surg Oncol 2007;5:56.
6. Sinha R, Anderson DE, McDonald SS, et al.: Cancer risk and diet in India. J Postgrad Med 2003;49:222-228.
7. Pal. S, Sengupta SK: Breast Cancer in West Bengal, an epidemiological study. Ind J Cancer 1980;17:153-158.
8. Shukla NK, Seenu V, Goel AK, et al.: Male breast cancer: A retrospective study from a regional cancer center in northern India. J Surg Oncol 1996;61(2)143-148.
9. Hirschhorn JN, Daly MJ: Genome-wide association studies for common diseases and complex traits. Nature Rev Genet 2005;6:95-108. (Pubitemid 40179532)
10. Kibriya MG, Jasmine F, Argos M, et al.: A pilot genome-wide association study of early-onset breast. Breast Cancer Res Treat 10.1007/s10549-008-0039-9
11. James HCR, Quinn JE, Mullan PB, et al.: BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist 2007;12:142-150.
12. Perou CM, Sørlie T, Eisen MB, et al.: Molecular portraits of human breast tumors. Nature 2000;406:747-752.
13. Waldman FM, DeVries S, Chew KL, et al.: Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. J Natl Cancer Inst 2000;92:313-320.
14. O'Connell P, Pekkel V, Fuqua SA, et al.: Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 1998;90:697-703.
15. Agrawal A, Murphy RF, Agrawal DK: DNA methylation in breast and colorectal cancers. Mod Pathol 2007;20:711-721. (Pubitemid 46933450)
16. Kim SJ, Kang HS, Chang HL, et al.: Promoter hypomethylation of the N-acetyltransferase 1 gene in breast cancer. Oncol Rep 2008;19,663-668.
17. Bloushtain-Qimron N, Yao J, Snyder EL, et al.: Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci USA 2008;105:14076-14081.
18. Cucer N, Taheri S, Ok E, et al.: Methylation status of CpG islands at sites -59 to +96 in exon 1 of the BRCA2 gene varies in mammary tissue among women with sporadic breast cancer. J Genet 2008;87:155-158.
19. Elledge RM, Allred DC: The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 1994;32:39-47. (Pubitemid 24322246)
20. Varley J: TP53, hChk2, and the Li-Fraumeni syndrome. Methods Mol Biol 2003;222:117-129.
21. Pylkas K, Erkko H, Nikkila J, et al.: Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families. BMC Cancer 2008;8:146.
22. Miki Y, Swensen J, Shattuck-Eidens D, et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
23. Thompson D, Easton D: The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 2004;9:221-236. (Pubitemid 39545740)
24. Thomassen M, Hansen TV, Borg A, et al.: BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer. Acta Oncol 2008;47:772-777.
25. Valarmathi MT, Sawhney M, Deo SS, et al.: Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families. Hum Mutat 2004;23:205.
26. Hedau S, Jain N, Husain SA, et al.: Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. Breast Cancer Res Treat 2004;88:177-186.
27. Mills GB, Lu Y, Fang X, et al.: The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 2001;28:125-141.
28. Steelman LS, Navolanic PM, Sokolosky ML, et al.: Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 2008;27:4086-4095.
29. Meur NL, Martin C, Saugier-Veber P, et al.: Complete germline deletion of the STK11 gene in a family with Peutz-Jeghers syndrome. Eur J Hum Genet 2004;12:415-418.
30. Nakanishi C, Yamaguchi T, Iijima T, et al.: Germline mutation of the LKB1/STK11 gene with loss of the normal allele in an aggressive breast cancer of Peutz-Jeghers syndrome. Oncology 2004;67:476-479.
31. Prokopcova J, Kleibl Z, Banwell CM, et al.: The role of ATM in breast cancer development. Breast Cancer Res Treat 2007;104:121-128.
32. Ahmed KM, Dong S, Fan M, et al.: Nuclear factor-kB p65 inhibits mitogen-activated protein kinase signaling pathway in radioresistant breast cancer cells. Mol Cancer Res 2006;4:945-955.
33. Andersen TI, Gaustad A, Ottestad L, et al.: Genetic alterations of the tumor suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas. Genes Chromosomes Cancer 1992;4:113-121.
34. Damjanovich J, Berta A, Beck Z, et al.: Mutation of the Rb1 gene caused unilateral retinoblastoma in early age. Cancer Genet Cytogenet 2000;119:1-7.
35. Lee WH, Shew JY, Hong FD, et al.: The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 1987;329:642-645.
36. Buchkovich K, Duffy LA, Harlow E: The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 1989;58:1097-1105. (Pubitemid 19238187)
37. Bosco EE, Knudsen ES: RB in breast cancer: At the crossroads of tumorigenesis and treatment. Cell Cycle 2007;6:667-671. (Pubitemid 46535677)
38. Stirzaker C, Millar DS, Paul CL, et al.: Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Res 1997;57:2229-2237.
39. Watts CK, Brady A, Sarcevic B, et al.: Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 1995;9:1804-1813.
40. Foster SA, Wong DJ, Barrett MT, et al.: Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol 1998;18:1793-1801.
41. Hurd C, Khattree N, Dinda S, et al.: Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells. Oncogene 1997;15:991-995.
42. Bosco EE, Wang Y, Xu H, et al.: The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest 2007;117:218-228.
43. Buckler AJ, Pelletier J, Haber DA, et al.: Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. Mol Cell Biol 1991;11:1707-1712.
44. Loeb DM, Evron E, Patel CB, et al.:Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res 2001;61:921-925.
45. Miyoshi Y, Ando A, Egawa C, et al.: High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002;8:1167-1171.
46. Oji Y, Miyoshi Y, Kiyotoh E, et al.: Absence of mutations in the Wilms' tumor gene WT1 in primary breast cancer. Jpn J Clin Oncol 2004;34:74-77.
47. Clifford SC, Maher ER: Von Hippel-Lindau disease: Clinical and molecular perspectives. Adv Cancer Res 2001;82:85-105. (Pubitemid 32613383)
48. Kim M, Katayose Y, Li Q, et al.: Recombinant adenovirus expressing Von Hippel-Lindau-mediated cell cycle arrest is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1. Biochem Biophys Res Commun 1998;253:672-677.
49. Sourvinos G, Miyakis S, Liloglou TL, et al.: Von Hippel-Lindau tumor suppressor gene is not involved in sporadic human breast cancer. Tumor Biol 2001;22:131-136.
50. Mukhopadhyay D: The tumor suppressor von Hippel-Lindau gene product and metastasis: New thoughts on an old molecule. Am J Pathol 2006;168:367-369. (Pubitemid 43271136)
51. Nakamura E, Abreu-e-Lima P, Awakura Y, et al.: Clusterin is a secreted marker for a HIF-independent function of the VHL tumor suppressor protein. Am J Pathol 2005;168:574-584.
52. Jandrig B, Seitz S, Hinzmann B, et al.: ST18 is a breast cancer Tumor Suppressor Gene at human chromosome 8q11.2. Oncogene 2004;23:9295-9302.
53. Xiang S, Coffelt SB, Mao L, et al.: Period-2: A tumor suppressor gene in breast cancer. J Circadian Rhythms 2008;6:4.
54. Gentile M, Ahnström M, Schön F, et al.: Candidate tumor suppressor genes at 11q23 ± q24 in breast cancer: Evidence of alterations in PIG8, a gene involved in p53-induced apoptosis. Oncogene 2001;20:7753-7760.
55. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al.: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008;68:6084-6091.
56. Heinonen H, Nieminen A, Saarela M, et al.: Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer. BMC Genomics 2008;9:348.
57. Yarden Y, Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001;2:127-137.
58. Beeghly-Fadiel A, Kataoka N, Shu XO, et al.: Her-2/neu amplifi- cation and breast cancer survival: results from the Shanghai breast cancer study. Oncol Rep 2008;19:1347-1354.
59. Ordas J, Millan Y, Dios R, et al.: Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: An immunohistochemical and chromogenic insitu hybridization study. BMC Cancer 2007;7:179.
60. Nagai MA, da-Ros N, Neto MM, et al.: Cancer genetics gene expression profiles in breast tumors regarding the presence or absence of estrogen and progesterone receptors. Int J Cancer 2004;111:892-899.
61. González-Zuloeta Ladd AM, Vásquez AA, Rivadeneira F, et al.: Estrogen receptor a polymorphisms and postmenopausal breast cancer risk. Breast Cancer Res Treat 2008;107:415-419.
62. Carole R, Mendelson, Daniel B, Hardy J: Role of the Progesterone Receptor (PR) in the regulation of inflammatory response pathway and aromatase in the Breast. Steroid Biochem Mol Biol 2006;102:241-249.
63. Huang HJ, Neven P, Drijkoningen M, et al.: Association between tumor characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 2005;58:611-616.
64. Almasri NM, Al Hamad M: Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res. 2005;7:R598-R604.
65. Signoretti S, Marcotullio L-Di, Richardson A, et al.: Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002;110:633-641.
66. Traub F, Mengel M, Lück HJ, et al.: Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res Treat 2006;99:185-191.
67. Sonoda H, Inoue H, Ogawa K, et al.: Significance of Skp2 expression in primary breast cancer. Clinical Cancer Res 2006;12:1215-1220.
68. Ravaioli A, Monti F, Regan MM, et al.: p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemoendocrine treatments in node-negative early breast cancer. Ann Oncol 2008;19:660-668.
69. von Lintig FC, Dreilinger AD, Varki NM, et al.: Ras activation in human breast cancer. Breast Cancer Res Treat 2000;62:51-62.
70. Eckert LB, Repasky GA, U?lkü AS, et al.: Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Breast Cancer Res Treat 2000;62:51-62.
71. Liao DJ, Dickson RB: c-Myc in breast cancer. Endocr Relat Cancer 2000;7:143-164.
72. Pietilainen T, Lipponen P, Aaltomaa S, et al.: Expression of c-myc proteins in breast cancer as related to established prognostic factors and survival. Anticancer Res 1995;15:959-964.
73. Deming SL, Nass SJ, Dickson RB, et al.: c-Myc amplification in breast cancer: A meta-analysis of its occurrence and prognostic relevance. Br J Cancer 2000;83:1688-1695.
74. Cuny M, Kramar A, Courjal F, et al.: Relating genotype and phenotype in breast cancer: An analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res 2000;60:1077-1083.
75. Moullan N, Cox DG, Angèle S, et al.: Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev 2003;12:1168-1174.
76. Brewster AM, Jorgensen TJ, Ruczinski I, et al.: Polymorphisms of the DNA repair genes XPD (Lys751Gln) and XRCC1 (Arg399Gln and Arg194Trp): Relationship to breast cancer risk and familial predisposition to breast cancer. Breast Cancer Res Treat 2006;95:73-80.
77. Zhang L, Zhang Z, Yan W: Single nucleotide polymorphisms for DNA Repair Genes in breast cancer patients. Clin Chim Acta 2005;359:150-155. (Pubitemid 41116307)
78. Bernard-Gallon D, Bosviel R, Delort L, et al.: DNA repair gene ERCC2 polymorphisms and associations with breast and ovarian cancer risk. Mol Cancer 2008;7:36.
79. Dufloth RM, Costa S, Schmitt F, et al.: DNA repair gene polymorphisms and susceptibility to familial breast cancer in a group of patients from Campinas. Brazil Genet Mol Res 2005;4:771-782.
80. Leung HY, Yun-Wang Y, Leung LK: Differential effect of overexpressing UGT1A1 and CYP1A1 on xenobiotic assault in MCF-7 cells. Toxicology 2007;242:153-159. (Pubitemid 350087437)
81. Spivack SD, Hurteau GJ, Fasco MJ, et al.: Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors. Clin Cancer Res 2003;9:6002-6011.
82. van der Hel OL, Bueno-de-Mesquita HB, van Gils CH, et al.: Cumulative genetic defects in carcinogen metabolism may increase breast cancer risk (The Netherlands). Cancer Causes Control 2005;16:675-681.
83. Larsen MC, Angus WG, Brake PB, et al.: Characterization of CYP1B1 and CYP1A1 expression in human mammary epithelial cells: Role of the aryl hydrocarbon receptor in polycyclic aromatic hydrocarbon metabolism. Cancer Res 1998;58:2366-2374.
84. Shimada T, Oda Y, Gillam EM, et al.: Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM2009. Drug Metab Dispos 2001;29:1176-1182.
85. Rylander-Rudqvist T, Wedren S, Granath F, et al.: Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. Carcinogenesis 2003;24:1533-1539.